Furthermore, in a recently published randomized phase 3 clinical trial, additional application of alkylating agent lomustine to TMZ standard therapy was accompanied by a survival benefit for patients with newly-diagnosed MGMT promoter methylated glioblastoma [11]. The gene discussed is MGMT; the disease is glioblastoma.